A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL

Inclusion Criteria: * The volunteer must be: * Aged 12 to 50 years on the day of screening * Females must be unmarried, single, or widowed * Willing and able to give written informed consent * For adolescents aged 12 to 17 years on the day of screening written informed consent from a parent must be obtained and assent from them. All Participants * Uncomplicated PKDL of \> 6 month's duration * Available for the duration of the study * In otherwise good health as determined by medical history, physical examination, results of screening tests and the clinical judgment of a medically qualified Clinical Investigator * Negative for malaria on blood smear * Judged, in the opinion of a medically qualified Clinical Investigator, to be able and likely to comply with all study requirements as set out in the protocol * Willing to undergo screening for HIV, Hepatitis B and Hepatitis C * Leishmania PCR positive on the screening skin biopsy * For females only, willing to undergo urinary pregnancy tests on the day of screening, on the day of vaccination (prior to vaccination) and 7 and 42 days after vaccination. Exclusion Criteria: The volunteer may not enter the study if any of the following apply: * Has mucosal or conjunctival PKDL * Has had treatment for PKDL within 21 days * Receipt of a live attenuated vaccine within 60 days or other vaccine within 14 days of screening * Administration of immunoglobulins and/or any blood products within the three months preceding the plan…